
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company developing Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced that the first patient has been treated as part of its Phase […]